Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.57 |
| ▸ | NPC1 | O15118 | 8/20 | 0.57 |
| ▸ | RAB9A | P51151 | 8/20 | 0.57 |
| ▸ | HPGD | P15428 | 7/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 4/20 | 0.56 |
| ▸ | PKM | P14618 | 3/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.54 |
| ▸ | FLT1 | P17948 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12659577 | 0.81 | NPC1 (0.57) | SMN1; SMN2ALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL13596393 | 0.81 | NPC1 (0.56) | SMN1; SMN2ALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL28500913 | 0.79 | RAB9A (0.45) | SMN1; SMN2ALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL5951395 | 0.79 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL30061331 | 0.79 | RAB9A (0.45) | SMN1; SMN2ALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL28498751 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL30061152 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL687305 | 0.79 | ALDH1A1 (0.63) | SMN1; SMN2ALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL31599727 | 0.77 | NUDT1 (0.53) | FGFR1FLT1NUDT1 | |
| SCHEMBL5952765 | 0.77 | NPC1 (0.48) | SMN1; SMN2ALDH1A1NPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988378-B2 | 1 H-pyrazole and 4,5-disubstituted thiazole inhibitors of SYK | HOFFMANN-LA ROCHE INC. (CH) | 2018-06-05 | — | — | US | claimed |
| US-20150266874-A1 | 1 H-PYRAZOLE AND 4,5-DISUBSTITUTED THIAZOLE INHIBITORS OF SYK | HOFFMANN-LA ROCHE INC. | 2015-09-24 | — | — | US | claimed |
| WO-2014064134-A1 | 3,4-DISUBSTITUTED 1 H-PYRAZOLE AND 4,5-DISUBSTITUTED THIAZOLE INHIBITORS OF SYK | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-01 | — | — | WO | claimed |
| WO-2025111251-A1 | COMPOUNDS THAT INHIBIT POLO-LIKE KINASE 4 | EXELIXIS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-112047932-B | Pyrazole spleen tyrosine kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-11-08 | — | — | CN | disclosed |
| CN-112047932-A | Pyrazole spleen tyrosine kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2020-12-08 | — | — | CN | disclosed |
| US-9988378-B2 | 1 H-pyrazole and 4,5-disubstituted thiazole inhibitors of SYK | HOFFMANN-LA ROCHE INC. (CH) | 2018-06-05 | — | — | US | disclosed |
| US-9988378-B2 | 1 H-pyrazole and 4,5-disubstituted thiazole inhibitors of SYK | HOFFMANN-LA ROCHE INC. (CH) | 2018-06-05 | — | — | US | disclosed |
| US-9988378-B2 | 1 H-pyrazole and 4,5-disubstituted thiazole inhibitors of SYK | HOFFMANN-LA ROCHE INC. (CH) | 2018-06-05 | — | — | US | disclosed |
| US-20150266874-A1 | 1 H-PYRAZOLE AND 4,5-DISUBSTITUTED THIAZOLE INHIBITORS OF SYK | HOFFMANN-LA ROCHE INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266874-A1 | 1 H-PYRAZOLE AND 4,5-DISUBSTITUTED THIAZOLE INHIBITORS OF SYK | HOFFMANN-LA ROCHE INC. | 2015-09-24 | — | — | US | disclosed |
| US-20100055094-A1 | PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3- [3-(5-M0RPHOOLIN-4-YL-METHYL-1H-BENZOIMIDAZOL-2-YL)- LH-1-PYRAZOL-4-YL]- UREA | ASTEX THERAPEUTICS LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100055094-A1 | PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3- [3-(5-M0RPHOOLIN-4-YL-METHYL-1H-BENZOIMIDAZOL-2-YL)- LH-1-PYRAZOL-4-YL]- UREA | ASTEX THERAPEUTICS LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100004232-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2010-01-07 | — | — | US | disclosed |
| US-20100004232-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2010-01-07 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| EP-1648426-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004232-A1 | Pharmaceutical Compounds | ERBB3, ABL1, RET | SMN1; SMN2 3461/4885ALDH1A1 3042/4885NPC1 3367/4885 |
| US-20150266874-A1 | 1 H-PYRAZOLE AND 4,5-DISUBSTITUTED THIAZOLE INHIBITORS OF SYK | SYK, BTK, IRAK4 | SMN1; SMN2 4821/4885ALDH1A1 2688/4885NPC1 4136/4885 |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | CDK1, AURKA, CDK2 | SMN1; SMN2 4105/4885ALDH1A1 1157/4885NPC1 2920/4885 |
| US-20100055094-A1 | PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3- [3-(5-M0RPHOOLIN-4-YL-METHYL-1H-BENZOIMIDAZOL-2-YL)- LH-1-PYRAZOL-4-YL]- UREA | LDHA, LDHB, PDK4 | SMN1; SMN2 2700/4885ALDH1A1 536/4885NPC1 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.